Artificial Intelligence
MEDIA ADVISORY: Expert Commentary and Insight Available on COVID-19 Drug Development
Perspectives on COVID-19 Vaccine and Therapeutic Development from Tufts Center for the Study of Drug Development
BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) — Experts from the Tufts Center for the Study of Drug Development are available to provide objective analysis and commentary on the nature and pace of development of vaccines and therapeutics to prevent and treat COVID-19.
Examples:
Experts available:
Kenneth I Kaitin, PhD, Professor and Director of Tufts CSDD Ken Getz, MBA, Professor and Deputy Director of Tufts CSDD Joseph A. DiMasi, PhD, Research Associate Professor and Director of Economic Analysis Mary Jo Lamberti, PhD, Research Assistant Professor and Associate Director of Sponsored Research ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT
The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the efficiency and productivity of pharmaceutical R&D. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.
Cell: 781-771-7729 Email: kenneth.kaitin@tufts.edu
Cell: 617-590-4175 Email: kenneth.getz@tufts.edu
Cell: 617-777-4402 Email: joseph.dimasi@tufts.edu
Cell: 781-820-2613 Email: mary_jo.lamberti@tufts.edu